Quest Diagnostics raises 2026 outlook as revenue grows 10% and adjusted EPS jumps 15%

Quest Diagnostics raised its full-year forecast after third-quarter revenue grew 10% on strong organic demand from physicians, hospitals and consumers.

The lab-testing company now expects 2026 revenue of $12.065 billion to $12.105 billion, up from $11.95 billion to $12.05 billion, and adjusted EPS of $11.25 to $11.35, up from $11.05 to $11.25, according to the earnings release it filed with an 8-K on Thursday. It lifted its reported EPS forecast to $10.21 to $10.31.

Third-quarter revenue reached $3.10 billion. Reported diluted EPS rose 28.7% to $2.78, and adjusted EPS climbed 15.4% to $3.00.

"Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness," Chairman, CEO and President Jim Davis said in the release. He also credited "productivity gains from automation and AI."

Deals and products

Quest said it finalized an agreement to buy select outreach lab assets from a health system in the Northeastern U.S. and announced that iPhone and iPad users in the U.S. will be able to buy a tailored Quest panel of more than 50 biomarkers through the Apple Health app later this year.

The earnings release came the same morning Quest disclosed, in a separate 8-K, that it is investigating unauthorized access to its Quanum LSM ordering and results system.

By the numbers

• Revenue: $3.10 billion, up 10.0%
• Reported EPS: $2.78, up 28.7%
• Adjusted EPS: $3.00, up 15.4%
• 2026 revenue outlook: $12.065 billion to $12.105 billion
• 2026 adjusted EPS outlook: $11.25 to $11.35

Sources

1. Quest Diagnostics Incorporated, Form 8-K (Item 2.02) with Exhibit 99.1 earnings release dated Oct. 22, 2026, accession 0001022079-26-000097
2. Quest Diagnostics Incorporated, Form 8-K (Item 8.01) dated Oct. 22, 2026, accession 0000947871-26-000941

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.